These data suggest hair loss on tirzepatide and hair loss on semaglutide can occur for some patients during active weight reduction, but it is not universal and was generally mild in studies
Using CJC1295 alone can result in underwhelming results compared to the synergistic effect of stacking
Clinical trial results, such as those discussed for investigational drugs like CT-388, will further contribute to the scientific understanding and validation of biased agonism in the treatment of metabolic diseases
Nadelmans practice is here to support you every step of the way
This last paragraph was clearly not kept in mind when decisions on cost saving were made
Most common AEs: nausea, diarrhea, vomiting, constipation mostly mild-to-moderate Onset: events concentrated during the 20-week titration period Discontinuation due to AEs: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% placebo Serious AEs: similar incidence across tirzepatide and placebo groups New signals: none identified beyond the known GLP-1 / GIP class profile Clinical significance Why SURMOUNT-1 reset the field Three observations stood out when SURMOUNT-1 was published in NEJM in 2022, and they still shape how Dr
